TruWealth Advisors LLC Acquires New Position in Bristol-Myers Squibb (NYSE:BMY)

TruWealth Advisors LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 202,426 shares of the biopharmaceutical company's stock, valued at approximately $12,346,000.

A number of other large investors also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $26,000. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $28,000. Transce3nd LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $28,000. Finally, Global Wealth Strategies & Associates lifted its holdings in shares of Bristol-Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 275 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Up 1.2%

NYSE BMY traded up $0.58 during trading on Friday, hitting $48.42. The company had a trading volume of 9,231,487 shares, compared to its average volume of 13,057,598. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company has a market cap of $98.54 billion, a price-to-earnings ratio of -10.95, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The company's fifty day moving average is $49.34 and its 200-day moving average is $55.06.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the prior year, the business earned ($4.40) EPS. On average, sell-side analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BMY shares. UBS Group lowered their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Wall Street Zen lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Jefferies Financial Group lowered their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, Wells Fargo & Company upped their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $58.00.

Insider Buying and Selling

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.